...
首页> 外文期刊>International Journal of STD & AIDS >Revertant multiresistant HIV in chronically infected drug naïve patients: when baseline resistance testing is not enough
【24h】

Revertant multiresistant HIV in chronically infected drug naïve patients: when baseline resistance testing is not enough

机译:慢性感染药物初治患者的可逆性多耐药性HIV:基线耐药性测试还不够时

获取原文
获取原文并翻译 | 示例

摘要

We present a patient with chronic HIV-1 infection and primary multi-drug resistance, the magnitude of which was underestimated by the baseline genotypic resistance testing (GRT) due to reversion of some of the mutations of the transmitted strain. This resulted in complete failure of his first antiretroviral regimen with rapid appearance of presumably archived mutations to more than one antiretroviral classes. Interestingly, his viral load remained high even in the presence of the M184V mutation. Baseline GRT in chronic HIV infection may not give adequate information in the presence of acquired multi-drug-resistant HIV strains, which have one or more of their mutations reverted. The presence of 215 codon polymorphisms should alert physicians to the possible coexistence of archived nucleoside and non-nucleoside reverse transcriptase inhibitor mutations. In such a case, initiation of a regimen with a low genetic barrier to resistance may not be the best choice and, if done, should be done cautiously and with more frequent monitoring of treatment response than usual.
机译:我们介绍了一名患有慢性HIV-1感染和原发多药耐药性的患者,由于传播菌株的某些突变回复,其基线基因型耐药性测试(GRT)低估了患者的病情。这导致他的第一个抗逆转录病毒治疗方案完全失败,并迅速出现了可能归类为多个抗逆转录病毒类别的突变。有趣的是,即使存在M184V突变,他的病毒载量仍然很高。在获得的具有多重耐药性的获得性多重耐药性HIV病毒株的存在下,慢性HIV感染的基线GRT可能无法提供足够的信息。 215个密码子多态性的存在应提醒医生注意已归档的核苷和非核苷逆转录酶抑制剂突变的可能共存。在这种情况下,启动抗药性低遗传屏障的方案可能不是最佳选择,并且如果这样做,应谨慎进行,并且比平常更频繁地监测治疗反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号